The architecture firm Scott Brownrigg is moving deliberately into life sciences real estate. The practice is positioning itself to compete for laboratory and research facility commissions as pharmaceutical and biotech campuses expand across Europe.
This signals a strategic reorientation or expansion of existing expertise within a market increasingly pursued by specialised planning practices. Competition in this segment is intensifying as developers and operators prioritise sustainable, flexible research infrastructure.
For design consultants and project teams, this reflects broader market consolidation: generalist practices are either building dedicated life sciences capabilities or losing ground to specialists. The shift matters for procurement professionals selecting architects for laboratory-intensive projects, particularly those requiring compliance with regulated manufacturing standards and advanced containment systems.
Scott Brownrigg's move underscores how real estate sector momentum—driven by nearshoring trends and public investment in domestic pharma capacity—creates competitive pressure across the design supply chain.
